Rejected from BMC Medicine? The 6 Best Journals to Submit Next

BMC Medicine is the flagship general-medicine journal in the BMC series, published by Springer Nature. Its editors screen for one thing above all: does this finding matter to clinicians, public-health practitioners, or policymakers across medicine, rather than only to one subspecialty? That single filter explains most rejections.

The journal runs a hybrid editorial model. In-house professional editors handle the initial triage and the well-known fast desk decision, then academic editors with clinical expertise manage peer review. The triage is quick, which is why a scope mismatch surfaces within days rather than months. A rejection that arrives fast is almost always an editorial-fit decision, not a judgment on your statistics.

Three editorial questions drive the desk decision:

• Breadth. Does the result interest readers beyond a single specialty? A strong cardiology cohort study can be desk-rejected here not because it is weak, but because BMC Cardiovascular Disorders is the better home.

• Advance. Does the paper move the field, or confirm what is already known in a new sample? BMC Medicine is selective for an open-access journal and wants a clear advance.

• Readership fit. Would a general-medicine and policy audience read this, or is it a methods paper, a pilot, or a basic-science study with a thin clinical frame?

If your rejection letter mentioned scope, fit, breadth, or "more suitable for a specialist journal," the science is probably fine. You have a positioning problem, and positioning problems are fixable at the next journal.

The right next venue depends on whether your rejection was about breadth, advance, or soundness. This shortlist covers the realistic moves for a paper that BMC Medicine declined.

Source: PLOS, JAMA Network, BMC/Springer Nature, BMJ, eLife, and Springer Nature author pages and APC schedules (accessed June 2026). Figures are sourced ranges; confirm current values on each journal's site before submitting.

PLOS Medicine is the closest lateral move for a broad clinical paper, especially one with a health-policy or global-health angle. It sits at a similar selectivity bar to BMC Medicine, so it is a lateral move, not a step down. The higher APC is the trade-off.

JAMA Network Open is the better lateral home for a broad clinical study that leans toward US practice and clinical-outcomes data. It is more selective than its acceptance rate suggests because the AMA editorial standard is demanding, but it publishes a high volume across all of clinical medicine.

A BMC series specialty journal is the right move when the rejection said your work was too specialist. BMC Cancer, BMC Public Health, BMC Cardiovascular Disorders, and BMC Health Services Research want exactly the focused clinical work that BMC Medicine pushes down. This is also where the transfer offer usually points.

BMJ Open and Scientific Reports are the soundness-led homes for work that is rigorous but modest in advance. They judge whether the science is valid, not whether it is field-changing, so an "incremental advance" rejection at BMC Medicine often becomes an acceptance here. eLife fits if your study is broad biomedical science and you are comfortable with its reviewed-preprint model, which replaces accept/reject with a public assessment.

Before you choose, a BMC Medicine manuscript fit check can tell you whether the rejection was scope, advance, or a deeper reporting gap that would follow the paper to the next journal too.

The mistake after a BMC Medicine rejection is to drop straight to a low-bar journal. Use a deliberate ladder instead, and route through the BMC transfer system where it fits.

Broad clinical paper, rejected for fit not quality? Stay at the same tier. Try PLOS Medicine first if there is a policy or global-health angle, or JAMA Network Open if the work is clinical-outcomes data with US relevance. Only step down to BMJ Open or Scientific Reports if both decline.

Rejected as "too specialist"? This is the BMC transfer system's home turf. The BMC Transfer Desk can move your manuscript, and any reviews, to a sister journal such as BMC Cancer, BMC Public Health, or BMC Health Services Research with no reformatting. The portfolio transfer carries your editorial history and any reviewer reports across, which can eliminate a full round of re-review. The transfer never happens without your agreement, so treat the offer as one strong option on the ladder, not an obligation.

Rejected after peer review? Fix what the reviewers flagged before you move, because those concerns will follow the paper. Then target the next tier with the prior reviews attached if the new journal accepts transferred reviews. Many do, and it shortens the timeline.

Rejected for incremental advance? Step to a soundness-led journal (BMJ Open, Scientific Reports, eLife) where validity, not novelty, is the bar. Do not keep resubmitting to advance-selective journals that will reject for the same reason.

The general rule: move laterally before you move down, and use a transfer offer only when the suggested journal is a genuine fit for your study type.

In our pre-submission review work with BMC Medicine submissions, the rejections we see most often cluster into four named rejection patterns, and three of the four are fixable before you resubmit anywhere. Each one maps to a specific BMC Medicine editorial triage pattern, and editors consistently reject for these reasons before peer review even begins. Knowing which one applies to your paper is the difference between a smart lateral move and a second fast desk rejection.

Pattern 1: the specialty paper wearing a general-medicine label. This is the most common BMC Medicine desk rejection we see. The study is a solid, focused piece of subspecialty research, but the abstract and cover letter never make the case that a cross-specialty readership should care. We repeatedly find the same tell: the abstract describes the result entirely in subspecialty terms and the discussion section never widens out to general clinical or policy implications.

The fix is not new data. It is reframing the abstract and the first paragraph of the discussion around the broad-relevance question, or accepting that a BMC series specialty journal is the honest home.

Pattern 2: the cover letter that argues study design instead of fit. BMC Medicine editors use the cover letter to judge fit before they read the manuscript. Across our BMC Medicine pre-submission reviews, the weakest cover letters recite the methods and headline result and never answer the only question triage cares about: why does a general-medicine and policy audience need this paper?

A cover letter that says "we conducted a multicenter cohort study and found X" loses to one that says "this is the first evidence that X changes management across primary and secondary care." Same study, different framing, different desk outcome.

Pattern 3: reporting-checklist gaps that the fast triage catches. The quick desk decision is not a light one. Missing or incomplete reporting documentation is a frequent reason for an early return: an RCT submitted without a complete CONSORT checklist and flow diagram, a systematic review without PRISMA 2020 documentation and a pre-registered PROSPERO protocol, or an observational study with a STROBE checklist where half the items point to "see Methods."

These gaps read as a soundness risk before peer review even starts. Fix the checklist and the data-availability statement before you submit anywhere, because every reputable next journal will ask for the same documents.

Pattern 4: the incremental-advance paper in a well-covered area. BMC Medicine wants a clear advance, not a confirmation in a new sample. We see methodologically clean manuscripts rejected because the contribution is "we replicated a known association in a different cohort" or "we added statistical mass to an established finding." This is the one pattern that reframing alone does not fix at an advance-selective journal.

The right move is a soundness-led venue (BMJ Open, Scientific Reports, eLife) that publishes valid work without requiring field-changing novelty, where the same paper is a strong fit rather than a weak one.

The practical takeaway: patterns 1, 2, and 3 are positioning and reporting fixes you make before resubmitting to a similar-tier journal. Pattern 4 is a signal to change tier, not to keep arguing the same advance to the same kind of editor.

Do not just resubmit the same file with a new cover sheet. A BMC Medicine rejection tells you something, and the next editor will see the same paper unless you act on it.

Start by reading the rejection letter literally and matching what it says to the right action:

If reviewers questioned the advance itself rather than the presentation, that is the signal to change tier, not to keep arguing the same point to the same kind of editor.

Be honest about the appeal question. An appeal is worth it only when you can point to a concrete factual error in the assessment, for example a reviewer who misread your primary endpoint or missed a pre-registered analysis. A general disagreement about importance is not grounds for a successful appeal, and appeals cost weeks. In nearly every case, a well-targeted resubmission elsewhere is faster than an appeal.

One more honest caution: resubmitting the same paper to BMC Medicine without an explicit invitation almost always earns a second fast desk rejection. Save BMC Medicine for a genuinely new version with new data and a clear breadth argument.